

DAFTAR PUSTAKA

1. Mosayyebi A, Manes C, Carugo D, Somani BK. Advances in Stent ureter Design and Materials. *Curr Urol Rep.* 2018;19(5).
2. Aggarwal SP, Priyadarshi S, Tomar V, Yadav SS, Gangkak G, Vyas N, et al. A randomized controlled trial to compare the safety and efficacy of Tadalafil and Tamsulosin in relieving Stent ureter related symptoms. *Adv Urol.* 2015;2015.
3. Lu J, Lu Y, Xun Y, Chen F, Wang S, Cao S. Impact of Endourological Procedures with or without Stent ureter on Sexual Function: A Systematic Review and Meta-Analysis. *BMC Urology.* 2020;20(1):1–8.
4. Vogt B, Chokri I. Histological Inflammation in Human Ureter either Healthy or Fitted with Double-Pigtail Stent or a Thin 0.3 F Suture Thread: A Preliminary Study. *Adv Uro.* 2020;2020.
5. Lange D, Bidnur S, Hoag N, Chew BH. Stent ureter-associated complications-where we are and where we are going. *Nat Rev Urol [Internet].* 2015;12(1):17–25. Available from: <http://dx.doi.org/10.1038/nrurol.2014.340>
6. Furuta A. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. 2018;3–8.
7. Tanidir Y, Mangir N, Sahan A, Sulukaya M. Turkish version of the Stent ureter Symptoms Questionnaire: linguistic and psychometric validation. *World J Urol.* 2017;35(7):1149–54.
8. Tae BS, Cho S, Jeon BJ, Choi H, Park JY, Cho SY, et al. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. *BJU Int.* 2018;122(5):866–72.
9. Otsuki H, Yamasaki T, Hori S, Aoki H, Kosaka T, Uehara S, et al. The efficacy of mirabegron for the relief of stent ureter-related symptoms. *Acta Med Okayama.* 2020;74(2):145–50.



10. Tolls V, Kelly K, Nickel JC. Mirabegron as adjuvant treatment for patients with cystitis / bladder pain syndrome. 2018;12(3).

11. Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: A randomized controlled study. *J Int Med Res.* 2010;38(4):1436–41.

12. Beysens M, Tailly TO. Stent ureters in urolithiasis. *Asian J Urol* [Internet]. 2018;5(4):274–86. Available from: <https://doi.org/10.1016/j.ajur.2018.07.002>
13. Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stölzel M, Choudhury N, et al. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. *Eur Urol Focus*. 2017;3(6):629–38.
14. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis [Figure presented]. *Eur Urol*. 2018;74(3):324–33.
15. Camtosun A, Bicer S. The impact of Stent ureter on the quality of sexual life and job performance. *Clin Exp Obstet Gynecol*. 2020;47(2):199–201.
16. Zumstein V, Betschart P, Albrich WC, Buhmann MT, Ren Q, Schmid H-P, et al. Biofilm formation on stent ureters - Incidence, clinical impact, and prevention. *Swiss Med Wkly*. 2017 Feb;
17. Sighinolfi MC, Sighinolfi GP, Galli E, Micali S, Ferrari N, Mofferdin A, et al. Chemical and Mineralogical Analysis of Stent ureter Encrustation and Associated Risk Factors. *Urology*. 2015;86(4):703–6.
18. Fischer KM, Louie M, Mucksavage P. Stent ureter Discomfort and Its Management. *Curr Urol Rep*. 2018;19(8):5–8.
19. Gonzalez EJ, Arms L, Vizzard MA. The Role (s) of Cytokines / Chemokines in Urinary Bladder Inflammation and Dysfunction. 2014;2014.
20. Rodhe N, Löfgren S, Strindhall J, Matussek A. Cytokines in urine in elderly subjects with acute cystitis and asymptomatic bacteriuria. 2009;3432.



21. Boudreau C, Mariani MK, Yang Y, Grandvaux N, Gee K. Interleukin (IL)-6 inhibits IL-27- and IL-30- inflammatory responses in human monocytes. *Front Immunol*. 2018;9(FEB):1–16.
22. Argler S, Cramer R, Eiwegger T, Fujita H, Gomez E, et al. Interleukins, from 1 to 37, IL-38 and IL-39: Receptors, functions, and roles in diseases. *J Allergy Clin Immunol*.

- 2011;127(3):701-721.e70.
23. Choy E. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. 2017;2(Suppl 2):1–5.
 24. Al-eisa A. Serum and Urine Interleukin-6 and Interleukin-8 Levels Do Not Differentiate Acute Pyelonephritis from Lower Urinary Tract Infections in Children. 2020;
 25. White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens [Internet]. 2018;12(11):768-778.e1. Available from: <https://doi.org/10.1016/j.jash.2018.08.001>
 26. Nachawati D, Patel J. Alpha Blockers. Encycl Toxicol Third Ed. 2021;
 27. Robinson D, Cardozo L. Solifenacin : pharmacology and clinical efficacy. Expert Rev Clin Pharmacol. 2009;2(3):239–53.
 28. Chapple CR, Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol. 2017;10(2):131–51.
 29. Zhou L, Cai X, Li H, Wang K. Effects of α -Blockers, Antimuscarinics, or Combination Therapy in Relieving Stent ureter-Related Symptoms: A Meta-Analysis. J Endourol. 2015 Jun;29(6):650–6.
 30. Liu Q, Luo D, Yang T, Liao B, Li H, Wang KJ. Protective Effects of Antimuscarinics on the Bladder Remodeling after Bladder Outlet Obstruction. Cell Physiol Biochem. 2017;44(3):907–19.
 31. Wood MW, Breitschwerdt EB, Gookin JL. Autocrine effects of interleukin-6 mediate acute-phase proinflammatory and tissue-reparative transcriptional responses of canine bladder mucosa. Infect Immun. 2011;79(2):708–15.



22. Villiger P, Li THUG, Koziol J, W BLZ. Interleukin-6 and interstitial cystitis. September):869–73.

Irano A, Carnicer-Caceres C, Valtierra-Carmeno N, Agraz-Pamplona I, Ramos-Jatem Escalante E, et al. Valor de los niveles urinarios de interleucina 6, factor de

- crecimiento epidérmico, proteína quimioattractante de monocitos de tipo 1 y factor de crecimiento transformante $\beta 1$ para la predicción de la extensión de las lesiones de fibrosis en biopsias de enf. Nefrología [Internet]. 2017;37(5):531–8. Available from: <http://dx.doi.org/10.1016/j.nefro.2016.11.017>
34. Grover S, Srivastava A, Lee R, Tewari AK, te AE. Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol. 2011;3(1):19–33.
 35. N. Altunal, A. Willke, O. Hamzaoglu Ureteral stent infections: a prospective study Braz J Infect Dis, 21 (2017), pp. 361-364, [10.1016/j.bjid.2016.12.004](https://doi.org/10.1016/j.bjid.2016.12.004)
 - 36.K.P. Balashanmugam, Rajaram, T. Palanisamy, Periyasamy, Sangameswaran, K. Kumar, et al. A study on the role of dj stenting in ureteric calculi patients after intracorporeal lithotripsy J Evol Med Dent Sci, 4 (2015), pp. 16563-16566, [10.14260/jemds/2015/2466](https://doi.org/10.14260/jemds/2015/2466)
 37. V.K. Chauhan, M.K. Singla, A. Dumra, N. Agarwal, A.S. Bawa Efficacy and safety of tadalafil in ureteric stent related symptoms: a double blind, prospective, randomised study Int J Res Med Sci, 7 (2019), p. 1472, [10.18203/2320-6012.ijrms20191523](https://doi.org/10.18203/2320-6012.ijrms20191523)

